Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Randomized, Prospective, Double blind, Parallel group, Multi-center Study to determine the Safety and Efficacy of GRANEXIN GEL in the Treatment of Diabetic Foot Ulcers

Next Previous
X
Search
Trial Profile

A Phase II, Randomized, Prospective, Double blind, Parallel group, Multi-center Study to determine the Safety and Efficacy of GRANEXIN GEL in the Treatment of Diabetic Foot Ulcers

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ACT 1 (Primary)
  • Indications Diabetic foot ulcer
  • Focus Therapeutic Use

    • Most Recent Events

    • 15 Jul 2013 Positive data will be reported at the International Gap Junction Conference (IGJC), according to a FirstString media release. Top-line data were reported in the media release.
    • 15 Jul 2013 Primary endpoint 'Wound-closure' has been met, according to a FirstString media release.
    • 24 Jul 2012 Actual initiation date changed from 7 Sep 2011 to 7 Oct 2011 as reported by Clinical Trials Registry - India.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top